ProfileGDS5678 / 1424066_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 83% 81% 83% 87% 88% 85% 86% 84% 84% 83% 84% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1283784
GSM967853U87-EV human glioblastoma xenograft - Control 26.1636883
GSM967854U87-EV human glioblastoma xenograft - Control 36.1040283
GSM967855U87-EV human glioblastoma xenograft - Control 45.9117981
GSM967856U87-EV human glioblastoma xenograft - Control 56.1722183
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.398287
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6604788
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3862685
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4970386
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1930284
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1990384
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1822983
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1773984
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2665385